Tempest CEO to Present at H.C. Wainwright Conference

Event summary

Tempest Therapeutics CEO Matt Angel to present at H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026.
Webcast available on Tempest’s investor relations website.
Tempest focuses on in vivo CAR-T therapies for cancer and autoimmune diseases.
Lead product candidate TPST-4003 targets CD19/BCMA and CD7 for immune reset.

The big picture

Tempest’s participation in the H.C. Wainwright conference underscores its push to engage investors amid a crowded biotech landscape. The focus on in vivo CAR-T therapies aligns with broader industry trends toward targeted immune therapies, but Tempest must demonstrate clear differentiation to attract funding and partnerships. The presentation will be a key test of its ability to communicate its strategic vision and clinical pipeline progress.

What we're watching

Clinical Progress: How Tempest’s presentation will highlight advancements in TPST-4003 and its potential for broad immune reset.
Market Positioning: Whether Tempest can differentiate itself in the competitive CAR-T therapy space.
Funding Strategy: The pace at which Tempest secures additional capital to support its clinical-stage programs.